BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of ...

MRM Health has received clearance from the FDA for its IND application, enabling the company to start the STARFISH-UC Phase ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

These results tout the potential Eli Lilly's Taltz-Zepbound as the new SoC for PsA patients with comorbid obesity.

The Mount Sinai TCC has introduced an AI clinical trial matching platform, PRISM, to improve access to cancer research ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

Treatment with the tumour necrosis factor receptor 2 (TNFR2)-targeting monoclonal antibody (mAb) plus Keytruda was also found ...

The trial enrolled 44 participants with symptomatic oHCM. Credit: NMK-Studio / Shutterstock.com. Bristol Myers Squibb (BMS) has announced positive top line results from the Phase III SCOUT-HCM trial ...

MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.